JP2025507416A5 - - Google Patents

Info

Publication number
JP2025507416A5
JP2025507416A5 JP2024548656A JP2024548656A JP2025507416A5 JP 2025507416 A5 JP2025507416 A5 JP 2025507416A5 JP 2024548656 A JP2024548656 A JP 2024548656A JP 2024548656 A JP2024548656 A JP 2024548656A JP 2025507416 A5 JP2025507416 A5 JP 2025507416A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
eye
condition
steroids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024548656A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025507416A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2023/050103 external-priority patent/WO2023154980A1/en
Publication of JP2025507416A publication Critical patent/JP2025507416A/ja
Publication of JP2025507416A5 publication Critical patent/JP2025507416A5/ja
Pending legal-status Critical Current

Links

JP2024548656A 2022-02-15 2023-02-15 解剖学的及び機能的な網膜萎縮の治療 Pending JP2025507416A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2022900318A AU2022900318A0 (en) 2022-02-15 Treatment of anti-vegf refractory ophthalmic retinal eye conditions
AU2022900318 2022-02-15
PCT/AU2023/050103 WO2023154980A1 (en) 2022-02-15 2023-02-15 Treatment of anatomical and functional retinal atrophies

Publications (2)

Publication Number Publication Date
JP2025507416A JP2025507416A (ja) 2025-03-18
JP2025507416A5 true JP2025507416A5 (enExample) 2026-02-24

Family

ID=87577221

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024548656A Pending JP2025507416A (ja) 2022-02-15 2023-02-15 解剖学的及び機能的な網膜萎縮の治療

Country Status (6)

Country Link
US (1) US20250387410A1 (enExample)
EP (1) EP4479061A4 (enExample)
JP (1) JP2025507416A (enExample)
CN (1) CN119031918A (enExample)
AU (1) AU2023221950A1 (enExample)
WO (1) WO2023154980A1 (enExample)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019207515B2 (en) * 2018-01-10 2024-11-14 Eye Co Pty Ltd Medical device and pharmaceutical composition for treatment of an eye disease or condition
PL3684370T3 (pl) * 2018-02-26 2025-07-28 Eye Co Pty Ltd. Kompozycja i leczenie zaniku geograficznego fludrokortyzonem

Similar Documents

Publication Publication Date Title
CN101553235B (zh) 甾族化合物前药在治疗眼后段疾病中的用途
JP7519413B2 (ja) 眼科用薬剤組成物、眼科用キット、及びその医学的応用
Abadia et al. Clinical applications of dexamethasone for aged eyes
JP2002539263A (ja) 徐放性副腎皮質ステロイドによる網膜症の治療方法または防止方法
EP2309980A1 (en) Ophthalmic compositions for treating pathologies of the posterior segment of the eye
JP2010536797A5 (enExample)
US20070134244A1 (en) Combination treatment for pathologic ocular angiogenesis
FI4185318T3 (fi) Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon
KR102266014B1 (ko) 안질환 예방 또는 치료용 점안 조성물
RU2015145134A (ru) Местное лечение воспалительных офтальмологических заболеваний
CN100431544C (zh) 用于治疗病理性眼血管生成的糖皮质激素制剂
JP2025507416A5 (enExample)
WO2015089559A1 (en) Optimising bioavailability of intra vitreally injectable steroids
US20070043006A1 (en) Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis
JP7793640B2 (ja) Ｎ－オキソピリジン化合物の発生を抑制する眼疾患の予防または治療用点眼組成物
US20110257186A1 (en) Compositions and methods for treating visual disorders
US20250387410A1 (en) Treatment of anti-vegf refractory ophthalmic retinal eye conditions
Bakri et al. Antiangiogenic agents: intravitreal injection
US20090181933A1 (en) Use of steroids to treat persons suffering from ocular disorders
KR101541416B1 (ko) 후안부 질환 치료를 위한 스테로이드 전구약물의 용도
Kurz et al. Injectable intraocular corticosteroids
Oluleye et al. Intravitreal Triamcinolone in Posterior Segment Diseases–Method of administration
JP2007056012A (ja) 軟膏様組成物を用いた後眼部組織への非侵襲性ドラッグデリバリーシステム